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ABSTRACT CD30 (TNFRSF8), a tumor necrosis factor receptor family protein, and CD30 vari-
ant (CD30v), a ligand-independent form encoding only the cytoplasmic signaling domain, are 
concurrently overexpressed in transformed human embryonic stem cells (hESCs) or hESCs 
cultured in the presence of ascorbate. CD30 and CD30v are believed to increase hESC sur-
vival and proliferation through NFκB activation, but how this occurs is largely unknown. Here 
we demonstrate that hESCs that endogenously express CD30v and hESCs that artificially 
overexpress CD30v exhibit increased ERK phosphorylation levels, activation of the canonical 
NFκB pathway, down-regulation of the noncanonical NFκB pathway, and reduced expression 
of the full-length CD30 protein. We further find that CD30v, surprisingly, resides predomi-
nantly in the nucleus of hESC. We demonstrate that alanine substitution of a single threonine 
residue at position 61 (T61) in CD30v abrogates CD30v-mediated NFκB activation, CD30v-
mediated resistance to apoptosis, and CD30v-enhanced proliferation, as well as restores 
normal G2/M-checkpoint arrest upon H2O2 treatment while maintaining its unexpected sub-
cellular distribution. Using an affinity purification strategy and LC-MS, we identified TRAF2 as 
the predominant protein that interacts with WT CD30v but not the T61A-mutant form in 
hESCs. The identification of Thr-61 as a critical residue for TRAF2 recruitment and canonical 
NFκB signaling by CD30v reveals the substantial contribution that this molecule makes to 
overall NFκB activity, cell cycle changes, and survival in hESCs.
INTRODUCTION
CD30 (TNFRSF8) is a cancer-associated cell surface antigen and a 
member of the tumor necrosis factor receptor (TNFR) superfamily 
(Smith et al., 1993; Gedrich et al., 1996). It is a biomarker for malig-
nant Reed–Sternberg cells in Hodgkin’s disease (Durkop et al., 1992), 
embryonal carcinoma (EC) cells (Durkop et al., 2000), anaplastic 
large-cell lymphoma (ALCL) cells (Zheng et al., 2003), in vitro–cul-
tured aneuploid human embryonic stem cells (hESCs; Pera et al., 
1997; Herszfeld et al., 2006), and hESCs and induced pluripotent 
stem cells cultured in the presence of ascorbate. A cryptic promoter 
in intron 10 of CD30 drives expression of CD30 variant (CD30v; Horie 
et al., 1996), an mRNA that codes for only the cytoplasmic signaling 
tail of CD30 and is typically coexpressed with the full-length CD30 
(CD30FL; Horie et al., 1996, 1999), but, unlike CD30FL, CD30v does 
not require CD30 ligand (Horie et al., 1996). In agreement with the 
observation that CD30FL and CD30v lack an intrinsic kinase domain, 
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near-background levels, indicating that T61 is critical for NFκB acti-
vation by CD30v (Figure 1C).
Thr-61 in CD30v is critical for CD30v–TRAF2 interaction
To understand better the role that CD30v plays in hESC biology and 
identify candidate proteins interacting with this threonine (possibly 
a novel TRAF protein as suggested by Horie et al., 1998), we estab-
lished HES3 hESCs that stably overexpress hemagglutinin (HA)-
tagged wild-type CD30v (WT) and T61A mutant (T61A) proteins. As 
controls, we generated hESCs that contain an empty vector (OE 
V/C) or vector overexpressing enhanced green fluorescent protein 
(EGFP). Generation and maintenance of stable lines were performed 
in a standard hESC medium (NutriStem) that contains ascorbate, 
resulting in expression of endogenous CD30FL and CD30v proteins 
alongside artificially overexpressed HA-tagged wild-type or mutant 
CD30v proteins.
Western blot analysis revealed that T61 mutant and WT CD30v 
were overexpressed to similar levels (∼20-fold; Figure 2, A and B). 
We reported earlier (Chung et al., 2010b) that CD30v overexpres-
sion leads to CD30FL mRNA down-regulation and now show that 
this also leads to a decrease in CD30FL protein levels, consistent 
with the idea of existence of a negative-feedback mechanism by 
CD30 signaling (Figure 2, A and C). Of note, because this mecha-
nism is observed in both WT and T61A CD30v proteins, we con-
clude that this negative-feedback mechanism likely occurs indepen-
dently of the T61-driven NFκB activation.
Previous studies assumed that, like CD30FL, the shorter, ligand-
independent CD30v would be located extranuclearly. However, 
when we performed nuclear-cytoplasmic fractionation of GFP, WT, 
and T61A cells, we found both WT and T61A CD30v predominantly 
in the nuclear fraction that contained the majority of Histone-H3 and 
the entire OCT4 transcription factor expression and to a smaller ex-
tent in the cytosolic fraction containing glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). As shown in Figure 2D, immunostaining 
with anti-HA antibody further confirmed the predominantly nuclear 
localization of both WT and T61A-mutant HA-tagged CD30v pro-
teins (Figure 2E). Immunostaining with anti-TRAF2 antibody (Figure 
2D) showed that whereas TRAF2 is predominantly cytoplasmic, a 
small proportion of TRAF2 is also present in the nucleus (Figure 2E). 
We thus conclude that in hESCs, CD30v is a predominantly nuclear 
protein and that mutation of Thr-61 does not interfere with its sub-
cellular localization.
We next examined the effect of WT and T61A CD30v expression 
on the expression of NFκB proteins and NFκB target genes. WT 
CD30v overexpression leads to an increase in transcription of ca-
nonical NFκB proteins RELA and NFκB1 and its downstream targets 
BNIP3 and VCAM1 and a concomitant decrease in levels of the 
noncanonical NFκB RELB gene (Supplemental Figure S1B). Con-
versely, expression of the mutant T61A CD30v protein, in agree-
ment with its impaired NFκB-activating potential, displays no in-
crease in RELA, NFκB1, or BNIP3 and a decrease in VCAM1 
expression, with BNIP3 and VCAM1 being bona fide RELA targets 
(Supplemental Figure S1B).
To identify the protein that interacts with T61 and drives CD30-
mediated NFκB activation, we immunoprecipitated HA-tagged 
proteins and their interacting partners with an anti-HA antibody and 
analyzed interacting proteins via liquid chromatography–mass spec-
trometry (LC-MS). EGFP-expressing hESCs were used to assess non-
specific protein interactions. Using this approach, we discovered that 
TRAF2 interacts with WT CD30v protein but not with the T61A-
mutant CD30v (Supplemental Table S3). This was subsequently 
validated using Western blot analysis (Figure 3A). These data strongly 
homo-oligomerization of CD30FL or CD30v is believed to activate 
CD30 signaling through the recruitment of signal-transducing mole-
cules such as members of the tumor necrosis factor receptor–associ-
ated factor (TRAF) family and the various TRAF-binding proteins 
(Horie et al., 1999; Schneider and Hübinger, 2002). Previous dele-
tion studies identified the extreme C-terminal 30 amino acids of 
CD30 as the domain responsible for interaction with TRAFs and 
subsequent NFκB activation (Gedrich et al., 1996; Aizawa et al., 
1997; Horie et al., 1998, 1999; Horie and Watanabe, 1998; 
Buchan and Al-Shamkhani, 2012) but also suggested contribu-
tions of more-N-terminal regions (Horie et al., 1998; Wright and 
Duckett, 2009). The discovery that aryl hydrocarbon nuclear 
translocator (ARNT) interacts with the CD30 signaling domain 
and suppresses CD30-mediated NFκB signaling in KARPAS-299 
cells through a negative feedback mechanism (Wright and Duck-
ett, 2009) revealed that CD30 signaling is more complex than 
was initially appreciated (Horie et al., 1998; Wright and Duckett, 
2009). For example, the precise molecular mechanism underly-
ing NFκB activation by CD30 remains largely to be elucidated 
(Gedrich et al., 1996; Aizawa et al., 1997; Horie et al., 1998; 
Buchan and Al-Shamkhani, 2012). Here we show that the bulk of 
CD30v, somewhat unexpectedly, resides in the nucleus, and, 
using site-directed mutagenesis and proteomics approaches, we 
identify a single threonine residue at position 61 in CD30v that is 
critical for TRAF2 interaction, NFκB activation, and downstream 
CD30-NFκB–dependent phenotypes in hESCs. Our data offer an 
explanation for the often disparate results of CD30 domain–
deletion studies and provide novel insight into the mechanism 
and roles(s) of CD30-dependent NFκB signaling in hESCs that it 
might be possible to exploit for hESC culture.
RESULTS
Thr-61 in CD30v is responsible for NFκB activation
Horie et al. (1998) showed that a novel D1 subdomain in CD30 
comprising amino acids 500–538, constituting the first 39 amino 
acids of its cytoplasmic tail, was sufficient for NFκB activation and 
that this involved recruitment of a yet-to-be-identified TRAF pro-
tein but not TRAF2 or TRAF5. Our bioinformatic analysis suggested 
the presence of a putative fork-head associated (FHA) binding do-
main at amino acids 59–65 in CD30v (equivalent to amino acids 
522–528 in full length [FL] CD30). We next created various mutant 
CD30v proteins with small deletions and point mutations within 
amino acids 59–65 of CD30v (Figure 1, A–C). Transient cotransfec-
tion of these mutant CD30v expression constructs with an NFκB 
luciferase reporter into HES3 hESCs revealed that deletion of amino 
acids 59–66 of CD30v (FHA CD30v ∆59–65) abrogated ∼90% of 
NFκB activity in hESCs (Figure 1B). Cotransfection with an AP1-lu-
ciferase reporter showed for the first time that CD30v can activate 
AP1 signaling but also that deletion of residues 59–65 (CD30v 
∆59–65) does not affect AP-1 activity, suggesting that this domain 
is specifically involved in NFκB activation downstream of CD30v 
(Figure 1B). In fact, no change in NFκB or AP1 activity was ob-
served for any of the other CD30v mutants we generated (Figure 
1B). We further report that, despite the bioinformatically predicted 
presence of putative sumoylation motifs, CD30v is not subject to 
SUMOylation (Supplemental Figure S1A). To determine the specific 
amino acid residues within the deleted region of CD30v that are 
responsible for NFκB activation, we mutated two putatively phos-
phorylatable threonine residues, one at position 61 (T61; Thr-524 in 
FL CD30) and one at position 66 (T66; Thr-529 in FL CD30), to ala-
nine (T61A, T66A). Altering T61 (T61A CD30v), but not T66, to ala-
nine significantly reduced the NFκB luciferase reporter activity to 
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TRAF2 expression after 96 h as compared 
with GFP-targeting control siRNA (siGFP)–
treated cells (Figure 3B). siTRAF2-treated 
WT CD30vOE hESCs displayed ∼50% re-
duction in NFκB-reporter activity as com-
pared with siGFP-treated CD30vOE hESCs 
(Figure 3C). TRAF2 siRNA treatment of 
hESCs expressing T61A-mutant CD30v fur-
ther reduced the already low NFκB reporter 
activity to background levels (Figure 3C). 
We conclude that CD30v expression makes 
a substantial contribution to NFκB activity in 
hESCs and that this is in large part mediated 
by interaction of TRAF2 with T61 in CD30v.
TRAF2-mediated, T61-dependent 
NFκB signaling by CD30v accelerates 
cell cycle progression of hESCs
After the establishment of several indepen-
dent WT and T61A-mutant CD30v-over-
expressing hESC lines, we consistently ob-
served significantly higher cell numbers in 
WT CD30v cells compared with the CD30v 
(T61A) mutant or control vector–transfected 
cells (Figure 4A). Cell cycle analysis indeed 
revealed a significant increase in percentage 
of cells in S phase (∼10% increase) accompa-
nied by a reduction in G0/G1 (by ∼4%) and 
G2/M (by ∼6%) phases in WT CD30v-express-
ing hESCs as compared with the T61A mu-
tant or the vector-only control cells (Figure 4B 
and Supplemental Figure S2A). Analysis of 
phospho–Histone H3 (Ser-10) levels, a marker 
of mitotic cells, indicated that hESCs that 
overexpress WT CD30v display a significantly 
lower (∼2.8%) fraction of cells in M phase as 
compared with the T61A mutant, parental, 
and vector-only controls (3.7%; Figure 4C 
and Supplemental Figure S2B). This appar-
ent increased cell cycle transition of CD30v-
overexpressing cells was accompanied by a 
significant increase in C-MYC, C-FOS, 
CYCLIN A2, CYCLIN E1, LIN28A, and 
CDC25A expression, a decrease in p27 
expression (Figure 4D), but unchanged CY-
CLIN D1, CYCLIN D2, CYCLIN D3, and p53 
mRNA expression (Figure 4D). The observa-
tion that these cell cycle–related changes 
were not observed in the CD30v (T61A) mu-
tant lines suggests that canonical NFκβ sig-
naling via the interaction of TRAF2 with T61 
in CD30 likely underlies the increased cell 
cycle progression in hESC and altered cell cycle regulation in CD30v-
expressing hESCs.
Mutation of Thr-61 in CD30v interferes with 
CD30v-conferred inhibition of apoptosis and H2O2-induced 
G2 cell cycle arrest
Because we previously reported that CD30FL (Herszfeld et al., 
2006) and CD30v overexpression (Chung et al., 2010b) enhances 
hESC survival, we next investigated whether interference with 
CD30-mediated canonical NFκB activation in the Thr-61-mutant 
suggest that T61 is critical for interaction of CD30v with TRAF2 and 
downstream NFκB signaling. We next verified that mutation of T61 
itself did not alter TRAF2 mRNA or protein expression (Figure 2A and 
Supplemental Figure S1B) or its intracellular localization (Figure 2E).
To confirm further the role of TRAF2 recruitment via T61 in 
CD30v-driven NFκB activation, we down-regulated TRAF2 expres-
sion using TRAF2 small interfering RNAs (siRNAs) in HES3 hESCs 
overexpressing T61A CD30v, or a WT or an empty vector (OE V/C) 
as controls, and analyzed NFκB activity using a NFκB-luciferase 
reporter. TRAF2 siRNA treatment caused a significant reduction in 
FIGURE 1: Thr-61 of CD30v is required for activation of NFκB signaling. (A) Graphical 
representation of the full-length CD30 (WT CD30FL) protein, highlighting Thr-524 within its 
cytoplasmic signaling domain. Wild-type (WT CD30v OE) and various mutant CD30v proteins 
highlighting Thr-61, which corresponds to Thr-524 within CD30 FL, are shown. (B) Measurement 
of NFκB and AP1 reporter activity via luciferase assay in HES3 hESCs transiently transfected 
with WT CD30v OE and mutant CD30v OE proteins. Schematics of the overexpressed WT 
and mutant CD30v proteins are shown next to reporter activity readings. Nontransfected 
and GFP-transfected cells were used as controls. The data are shown as mean fold changes ± SD 
of three independent experiments (#not significant, *p < 0.05, **p < 0.01, ***p < 0.001). 
(C) Measurement of NFκB activity via luciferase reporter assay in HES3 hESCs transiently 
-transfected with wild-type (WT CD30v OE) and mutant CD30v OE proteins. Graphical 
representation of the WT and mutant CD30v OE proteins. Nontransfected and GFP-transfected 
cells were used as controls. The data are shown as mean fold changes ± SD of three 
independent experiments (#not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
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FIGURE 2: CD30v is localized predominantly in the nucleus. (A) HES3 hESCs that stably overexpress GFP (control), WT, 
or T61A mutant CD30v proteins were established and validated by Western blotting with CD30v antibody. CD30FL and 
TRAF2 expression was also detected. (B) Average densitometric quantification, indicating fold change in CD30v 
expression normalized to GAPDH in WT and T61A CD30v–expressing hESCs compared with GFP hESCs. This was 
carried out using Image Lab Analysis Software (Bio-Rad). The data represent the mean fold changes ± SD of three 
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iodide (PI) staining of these same cell lines after challenge with 100 
μM H2O2 for 24 h confirmed that WT-CD30v expression effectively 
inhibits the accumulation of apoptotic cells in the sub-G0/G1 re-
gion and that mutation of Thr-61 abolishes this antiapoptotic ef-
fect of WT CD30v (Figure 5B and Supplemental Figure S2C). Our 
data further show that whereas WT CD30v-overexpressing cells 
CD30v-overexpressing cells affected cell survival. To this end, we 
subjected vector control, T61A, and WT cells to 200 μM H2O2 for 
3 h as previously performed (Herszfeld et al., 2006) and examined 
CASPASE-3 activation by immunofluorescence assay. As shown in 
Figure 5A, mutation of Thr-61 essentially abolished the ability of 
CD30v to inhibit H2O2-induced CASPASE-3 activation. Propidium 
FIGURE 3: TRAF2 interacts with CD30v via T61 to drive CD30v-mediated NFκB activation. (A) Validation of 
immunoprecipitation and LC-MS experiment in WT and T61A hESCs as compared with GFP hESCs, using Western blot 
analysis for TRAF2. CD30 (left blot) and HA tag (right blot) were used as loading controls. TRAF2, CD30, and HA tag 
expression detected in lysates of GFP, T61A, and WT cells was compared with their respective expression in HA-tag 
eluates from these cells after immunoprecipitation. (B) Validation of knockdown of TRAF2 in hESCs using siRNA 
targeted against TRAF2 mRNA (siTRAF2) using Western blot analysis. GFP siRNA (siGFP)–treated cells were used as a 
control. (C) Measurement of NFκB activity via luciferase assay in HES3 hESCs transiently cotransfected with 
overexpression vector control (OE V/C), WT, and T61A CD30v constructs and either siGFP or siTRAF2. Nontransfected 
cells (to detect background signal), OE V/C–transfected cells (to detect basal NFκB activity levels), and anti-GFP 
siRNA–transfected cells (to control for nonspecific siRNA effects) were used as controls to compare with NFκB activity 
in TRAF2 siRNA–treated cells. The data are shown as mean fold changes ± SD of three independent experiments 
(#not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
independent experiments (#not significant, *p < 0.05, **p < 0.01, ***p < 0.001). (C) Average densitometry quantification 
indicating percentage of CD30FL expression normalized to GAPDH in WT and T61A compared with GFP hESCs. 
Quantification was carried out using Image Lab Analysis Software. The data are shown as mean fold changes ± SD 
of three independent experiments (#not significant, *p < 0.05, **p < 0.01, ***p < 0.001). (D) Nuclear-cytoplasmic 
fractionation was performed on the GFP, T61A, and WT HES3 hESCs, followed by Western blotting with antibodies 
against GAPDH (cytoplasmic marker), OCT4, and Histone-H3 (nuclear marker), HA tag, CD30v, and TRAF2. 
Representative Western blots of two independent experiments. (E) Intracellular localization of CD30v (HA tag) and 
TRAF2 was also observed using confocal microscopy. Cells were stained simultaneously for nuclear DNA (DAPI). Scale 
bar, 5 μm. Inset images (for white squares) are displayed for DAPI + HA tag and DAPI-TRAF2 staining. The images are 
representative of at least three independent experiments.
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FIGURE 4: CD30v overexpression enhances hESC proliferation. (A) Fold change in cell numbers was measured over 5 d 
postseeding of WT and T61A cells as compared with OE V/C cells. The data are shown as mean fold changes ± SD of 
three independent experiments (#not significant, *p < 0.05, **p < 0.01, ***p < 0.001). (B) Cell cycle profile assessment of 
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CD30v activates canonical NFκB and extracellular 
signal–regulated kinase signaling in hESCs
AP1 lies downstream of the extracellular signal–regulated kinase 
(ERK) signaling pathway, and CD30 is known to modulate ERK sig-
naling in Hodgkin’s lymphoma (HL) cell lines (Zheng et al., 2003; 
Watanabe et al., 2011). Because we observed that CD30v is 
predominantly nuclear and enhances AP1 activity independently of 
display no significant change in G2/M or G0/G1 cell cycle after 
H2O2 challenge (Figure 5C and Supplemental Figure S2C), muta-
tion of Thr-61 restores the ability of hESC to undergo H2O2-in-
duced G2/M-phase arrest, leading to a significant decrease in the 
G0/G1 population (Figure 5C and Supplemental Figure S2C), signi-
fying that this occurs through a TRAF2-canonical NFκβ signaling 
cascade–dependent mechanism.
FIGURE 5: CD30v overexpression ameliorates H2O2-induced G2 cell cycle arrest. (A) Immunofluorescence analysis of 
active-CASPASE 3 in GFP, T61A, and WT hESCs that were either untreated or treated with 200 μM H2O2 for 3 h. Cells 
were stained simultaneously for nuclear DNA (DAPI). Scale bar, 10 μm. The images are representative of at least three 
independent experiments. (B) Percentage of dead cells (PI-positive cells using intact cell flow cytometry) in WT and 
T61A cells as compared with OE V/C cells after treatment with 100 μM H2O2 for 24 h. Cells not treated with H2O2 were 
used as controls. The data represent mean fold changes ± SD of three independent experiments (#not significant, 
*p < 0.05, **p < 0.01, ***p < 0.001). (C) Cell cycle profile assessment in WT and T61A cells as compared with OE V/C 
cells using samples obtained from B was carried out as per manufacturer’s instructions using BD Cycletest Plus DNA 
Reagent Kit (BD Biosciences). The data represent mean fold changes ± SD of three independent experiments 
(#not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
untransduced, OE V/C, and T61A- and WT- CD30v–overexpressing cells carried out as per manufacturer’s instructions 
using BD Cycletest Plus DNA Reagent Kit (BD Biosciences). The data are shown as mean ± SD of three independent 
experiments (#not significant, *p < 0.05, **p < 0.01, ***p < 0.001). (C) Phospho–Histone H3 (Ser-10) expression levels 
were measured using flow cytometry to determine the percentage of cells undergoing mitosis in parental, OE V/C, and 
T61A- and WT-CD30v–overexpressing cells. The data represent mean fold changes ± SD of three independent 
experiments (#not significant, *p < 0.05, **p < 0.01, ***p < 0.001). (D) mRNA expression analysis of various cell cycle 
regulators in T61A- and WT-CD30v–overexpressing cells as compared with OE V/C cells relative to GAPDH. The data 
represent mean fold changes ± SD of three independent experiments (#not significant, *p < 0.05, **p < 0.01, 
***p < 0.001).
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et al., 2005, 2011; Herszfeld et al., 2006; Amin and Lai, 2007; Wright 
and Duckett, 2009; Chung et al., 2010b; Buchan and Al-Shamkhani, 
2012). Others, however, report that CD30 expression does not alter 
NFκB signaling or cause pathological effects in HL and decreases 
proliferation in ALCL cells (Wright et al., 2007; Hirsch et al., 2008). In 
hESCs, canonical and noncanonical NFκB signaling act in an oppos-
ing manner, and canonical NFκB signaling enhances survival of 
hESCs (Hat et al., 2009; Yang et al., 2010).
Previous studies in HL and ALCL cells indicated that the C-termi-
nal 30 amino acids of CD30 were responsible for the interaction with 
TRAFs and subsequent CD30-dependent NFκB activation but that a 
yet-unidentified upstream signaling domain also plays a role (Gedrich 
et al., 1996; Aizawa et al., 1997; Horie et al., 1998; Buchan and Al-
Shamkhani, 2012). When we interrogated the entire cytoplasmic tail 
of CD30 for the presence of potential signaling domains, we identi-
fied a 7-amino acid putative FHA domain–binding motif (residues 
59–65), well away from the extreme C-terminus, which upon dele-
tion abrogated all NFκB signaling activity mediated by CD30v. Re-
placement of individual amino acids within and around this domain 
with alanine revealed that mutation of a single Thr-61 to alanine in 
CD30v prevents >90% of NFκB activation by CD30v. Immunopre-
cipitation of HA-tagged CD30v from hESCs followed by LC-MS next 
revealed that recruitment of TRAF2, a known CD30-interacting and 
NFκB-activating protein, requires Thr-61 for interaction with CD30v. 
This suggests that mutation of Thr-61, a site potentially subject to 
phosphorylation (not tested in this study), interferes with TRAF2 re-
cruitment to the more-C-terminal domains, perhaps by altering its 
conformation. The CD30 cytoplasmic tail (CD30v) sequence is pre-
dicted to be intrinsically unstructured (Kozlowski and Bujnicki, 2012) 
and shows limited similarity to any protein of known structure, sug-
gesting that it may only adopt a defined structure when binding with 
interacting signaling proteins. The only structural information avail-
able for CD30 is for an 8-residue fragment (residues 576–583 of 
CD30/113-120 of CD30v) bound to TRAF2 (Ye et al., 1999). In this 
structure, the peptide binds in an extended conformation to the 
outer surface of the trimer of the TRAF-C domain of TRAF2. A 
20-residue fragment from the cytoplasmic domain of CD40, the 
most closely related relative to CD30, complexed with the TRAF do-
main of TRAF3 shows that the CD40 fragment binds as a hairpin 
loop across the surface of the TRAF domain (Ni et al., 2000). We 
constructed a homology model (Eswar et al., 2008) of the analogous 
21-residue peptide corresponding to the C-terminal region of CD30 
(residues 574–594 of CD30/residues 111–131 of CD30v) bound to 
TRAF2 (Supplemental Figure S6). Although this model shows why 
the extreme C-terminus is important for TRAF2 binding and can ex-
plain why these fragments can independently bind TRAF2 in the 
absence of the rest of the CD30 cytoplasmic tail, it cannot explain 
why mutation of Thr-61/Thr-259 located some 50 residues N-termi-
nally to this TRAF2-binding region at the C-terminus of CD30v is so 
critical. In the absence of cocrystallization of the full cytoplasmic do-
main of CD30 and TRAF2, we can only speculate that this site im-
parts important conformational cues that allow presentation of these 
domains. Alternatively, it is possible that the Thr-61 site interacts with 
a spatially adjacent region of TRAF2 and that this initial event is criti-
cal in providing structure to the CD30 C-terminus and enables sub-
sequent TRAF2-binding events in the context of the full-length cyto-
plasmic domain. Because CD30v is known to interact with the same 
set of proteins as CD30FL and similarly induces ERK, AKT, and NFκB 
activation in a range of cell types (Smith et al., 1993; Aizawa et al., 
1997; Horie and Watanabe, 1998; Horie et al., 2002; Watanabe 
et al., 2005; Wright et al., 2007), we hypothesize that Thr-61 has an 
equally critical role in TRAF2-dependent NFκB activation in CD30FL 
the T61/TRAF2-driven NFκβ-activation cascade, we hypothesized 
that a novel CD30-interacting protein may be involved in the AP1 or 
ERK activation cascade and its nuclear translocation. To this end, we 
used HES2 and HES4 hESCs grown in Knock-Out Serum Replace-
ment (KOSR) minus ascorbate medium, allowing us to study CD30v-
mediated effects in cells that are free of any endogenous CD30FL or 
CD30v expression. We described this culture method earlier (Chung 
et al., 2010b); however, the generation and maintenance of stable 
lines in ascorbate-free medium is very cumbersome.
We first examined the NFκβ pathway in two different hESC 
lines—HES2 (Supplemental Figure S3, A and B) and HES4 (Supple-
mental Figure S4, A and B)—that are completely free of endoge-
nous CD30FL and CD30v expression as verified by immunostaining. 
We observed that in CD30v-overexpressing cells (CD30vOE), there is 
a substantial increase in canonical NFκβ signaling components—
RELA, phospho-RELA (S-529), p105, and p50—whereas the nonca-
nonical proteins RELB, NIK, p100, and p52 are down-regulated 
compared with CD30− hESCs (no CD30FL or CD30v expression), 
indicating an opposing relationship between these pathways and 
further substantiating the notion that these are direct effects of 
CD30v-mediated NFκB signaling.
We also examined the intracellular localization of CD30 proteins 
(both CD30FL and CD30v) in HES2 CD30Endo (Supplemental Figure 
S3C) and HES4 CD30Endo (Supplemental Figure S4C) hESCs grown 
in normal KOSR medium that contains ascorbate and hence triggers 
endogenous expression of both CD30FL and CD30v, and again we 
found a predominantly nuclear localization of CD30v, further sub-
stantiating that this phenotype is not an artifact arising from artifi-
cially overexpressing CD30v.
Finally, we examined expression and phosphorylation of ERKs in 
CD30− and CD30vOE HES2 hESCs. Western blot analysis (Supple-
mental Figure S5, A and B) reveals that P-ERK (Thr-202/Tyr-204) lev-
els are 1.5- to 2-fold higher in CD30vOE hESCs than in CD30− cells 
without affecting total ERK expression. We conclude that CD30v 
signaling activates canonical NFκβ and ERK signaling. The CD30 
domain responsible for ERK activation remains to be identified.
DISCUSSION
Deciphering how NFκβ and ERK signaling pathways govern survival, 
self-renewal, and pluripotency in human pluripotent stem cells is 
important for the development of safer culture conditions and their 
future application in regenerative medicine. CD30 is expressed in 
cells that are karyotypically abnormal, in hESCs exposed to ascor-
bate (Chung et al., 2010b), and its overexpression and constitutive 
NFκβ activation are the hallmarks of human germ cell tumors, em-
bryonal carcinoma cells, and malignant Hodgkin Reed–Sternberg 
cells and ALCL (Durkop et al., 1992, 2000; Horie et al., 1996, 1998, 
1999, 2002; Horie and Watanabe, 1998; Aizawa et al., 1997; Pera 
et al., 1997; Herszfeld et al., 2006; Amin and Lai, 2007; Hirsch et al., 
2008; Harrison et al., 2009).
The role of CD30 and particularly NFκβ signaling in driving path-
ological phenotypes in HL and ALCL and its precise role in enhanc-
ing survival of hESCs have been a matter of debate (Armstrong 
et al., 2006). Several studies report that elevated levels of the 
CD30FL and CD30v, the ligand-independent shorter isoform of 
CD30, which is usually coexpressed with the full-length receptor, 
induce canonical and noncanonical NFκβ, AKT, and ERK activation 
via interaction with TRAFs to enhance survival, proliferation, and 
transformation of HL and ALCL cells (Durkop et al., 1992, 2000; 
Smith et al., 1993; Gedrich et al., 1996; Horie et al., 1996, 1998, 
1999, 2002; Horie and Watanabe, 1998; Aizawa et al., 1997; 
Pera et al., 1997; Zheng et al., 2003; Nonaka et al., 2005; Watanabe 
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A prominent feature of hESCs that overexpress WT CD30v is the 
marked increase in cell proliferation rates. Indeed, WT CD30v-over-
expressing hESCs display a higher proportion of cells in S phase, a 
concomitant decrease of cells in G0/G1, and a decreased G2/M 
phase accompanied by reduced Histone-H3 phosphorylation. In 
agreement with this deregulation of the cell cycle in WT-CD30v–
overexpressing hESCs, the cells express increased levels of C-MYC, 
C-FOS, and LIN28A, genes known to regulate cell cycle and prolif-
eration and aid transformation (Singh and Dalton, 2009; Viswanathan 
et al., 2009; Li et al., 2012; Shyh-Chang and Daley, 2013), and CY-
CLIN A2, CYCLIN E1, and CDC25A, genes known to regulate G1/S 
and G2/M transitions (Murphy, 1999; Sandhu et al., 2000; Li et al., 
2012). Of importance, mutation of Thr-61 causes reversion of both 
the altered cell cycle profile and the expression of these genes to a 
pattern identical to that of untransduced or control vector–trans-
duced hESCs, indicating that the CD30v-mediated cell cycle changes 
are due to CD30-TRAF2–mediated NFκB signaling. What remain to 
be determined are the phosphorylation levels of the cyclins, which 
are known to be equally important for cell cycle control in hESCs 
(Singh and Dalton, 2009; Koledova, 2012).
We previously reported that CD30 expression inhibits H2O2-in-
duced apoptosis of hESCs (Herszfeld et al., 2006). Here we show 
that overexpression of CD30v also protects hESCs from H2O2-in-
duced apoptosis, as shown by the reduced levels of activated CAS-
PASE-3 and cell death rates, and that mutation of Thr-61 in CD30v 
abolishes this protective effect, indicating that TRAF2-mediated ca-
nonical NFκB signaling downstream of CD30v is responsible for 
conferring the resistance to H2O2-induced apoptosis to hESC. We 
observed no differences in expression, intracellular localization, or 
transcription of TRAF2 between vector control, T61A, or WT CD30v-
overexpressing hESCs, excluding the possibility that this effect is 
due to a CD30-mediated degradation of TRAF2 as reported in HEK-
293 cells (Duckett and Thompson, 1997).
An increased rate of progression through the G0/G1 and G2/M 
phases accompanied by a corresponding lengthening of the S 
phase and an ability to overcome H2O2-induced G2 cell cycle arrest 
are characteristics indicative of transformation. CD30 has a pleiotro-
pic effect on cell cycle and proliferation (Gruss et al., 1994; Pinto 
et al., 1996) and was shown to increase proliferation, modulate ex-
pression of cell cycle genes that accelerate G1/S transition, and me-
diate evasion of growth inhibition in peripheral blood T-cells (Kadin 
et al., 2001), autoreactive γδT-cells (Levi et al., 2000), cutaneous 
CD30+ ALCL cell lines (Levi et al., 2000), and HL cells (Wendtner 
et al., 1995; Watanabe et al., 2011) via NFκB and ERK activation 
(Levi et al., 2000; Watanabe et al., 2011). Nonaka et al. (2005) impli-
cated CD30 in cell transformation by showing that overexpression 
of CD30 in rat fibroblast at levels comparable with those in HL cells 
results in NFκB-dependent cell transformation. Our data show that 
TRAF2-mediated canonical NFκB signaling requiring Thr-61 in 
CD30v (and presumably Thr-524 in full length CD30) accelerates 
hESC proliferation and confers selective growth and survival advan-
tages (Draper et al., 2004; Singh and Dalton, 2009). CD30-mediated 
enhancement of survival of cells that have accumulated genetic or 
epigenetic changes that would otherwise be committed to apopto-
sis may enhance the propensity of the stem cell population to ac-
cumulate further DNA mutations, develop genetic instability, and 
thus aid in the transformation of hESCs (Herszfeld et al., 2006; 
Harrison et al., 2009; Mateizel et al., 2009; Chung et al., 2010a,b, 
2011). In this scenario, our data identifying the profound effects of 
mutating T61 on the CD30-NFκB signaling axis may allow for more 
efficient and specific ways to modulate this important signaling cas-
cade to prevent such CD30-mediated adverse effects in hESCs, 
as in CD30v. Remarkably, NFκB-reporter assays combined with 
siRNA knockdown of TRAF2 in hESC lines stably expressing T61mu-
tant or WT CD30v indicate that the majority of TRAF2-mediated ac-
tivation of NFκB signaling in hESC occurs through CD30v in a T61-
dependent manner, highlighting the importance of CD30v and 
CD30FL expression for hESC biology.
Surprisingly, we detected a majority of CD30v in the nucleus of 
hESCs, a phenomenon that is not affected by the mutation of Thr-
61. This raises the question as to how CD30v activates NFκB. We 
can envisage three possible scenarios: 1) the small amount of cyto-
plasmic CD30v leads to constitutive activation of the canonical 
TRAF2–IκB kinase (IKK)–NFκB pathway independently of CD30 li-
gand, 2) the TRAF2-CD30v cytoplasmic interaction facilitates CD30v 
nuclear accumulation, where it may play a direct role in regulating 
NFκB targets, or, most likely, 3) the small amount of nuclear TRAF2 
interacts with the nuclear CD30v to drive NFκB activation. There is 
indeed evidence that TRAF2 (Min et al., 1998), TRAF6 (Pham et al., 
2008), and IKKs, all initially believed to be obligatory cytoplasmic 
regulators of NFκB signaling, can enter the nucleus and interact 
with specific promoter regions, altering transcriptional activity and 
Histone-H3 phosphorylation (Yamamoto et al., 2003; Verma et al., 
2004). Furthermore, the cytoplasmic form of CD40, the closest 
TNFR relative to CD30 was, like CD30v, also found in the nucleus 
and shown to possess transcriptional activity (Lin-Lee et al., 2006). 
We can only speculate as to what the role of nuclear CD30v may be, 
but it is not unlikely that it may play a role in a negative-feedback 
regulatory mechanism that self-limits CD30FL expression. CD30FL 
expression is indeed down-regulated upon expression of CD30v, 
and we show that this occurs independently of Thr-61. In cell types 
other than hESCs, CD30 promoter activity was shown to be con-
trolled by AP-1, and we find that Thr-61 mutation does not affect 
CD30-mediated AP1 reporter activity or ERK activation. Wright and 
Duckett (2009) demonstrated that CD30FL expression can be regu-
lated at a posttranslational level in the cytoplasm through interac-
tion with ARNT and the CD30 C-terminus, leading to its accumula-
tion in cytoplasmic vesicles. Our present data showing that CD30v 
is predominantly nuclear, does not interact with ARNT, and yet still 
leads to repression of CD30FL suggest this may be an alternative 
mechanism for CD30FL regulation independently of ARNT.
It is possible that nuclear CD30v interacts with a completely 
novel family of signaling molecules driving new phenotypes. In-
deed, Ingenuity IPA analysis of our LC-MS data on proteins inter-
acting with wild-type CD30v revealed that whereas most of these 
CD30-interacting proteins were nuclear proteins involved in cell 
cycle, cell death, and survival, as expected, we also identified 
proteins concentrated in nuclear speckles and paraspeckles with 
roles in RNA posttranscriptional modifications, such as ARL6IP4, 
HNRNPU, NUDT21, RBM39, and SRSF2 (Supplemental Table S4). 
Of note, ARL6IP4 is exclusively expressed during G1/S transition 
and implicated in pre-mRNA splicing inhibition (Li et al., 2002); 
HNRNPU is known to promote MYC mRNA stabilization (Weidens-
dorfer et al., 2009); NUDT21 plays a key role in pre-mRNA 3′ 
cleavage and polyadenylation (Ruegsegger et al., 1996); RBM39 
is a known transcriptional coactivator for steroid nuclear recep-
tors ESR1/ER-α, ESR2/ER-β, and JUN/AP-1 and may be involved 
in pre-mRNA splicing process (Jung et al., 2002); and SRSF2 is 
necessary for the splicing of pre-mRNA and regulates cell cycle 
and apoptosis (Jang et al., 2009). In view of our data showing 
that CD30v-overexpressing cells possess substantially increased 
AP1 activity, C-MYC expression, increased rate of G1/S transition, 
and reduced apoptosis, a novel role for CD30v involvement in 
RNA posttranscriptional modification seems plausible.
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plasmids. Mutagenic primers and complementary primers were de-
signed to mutate the threonine residues at positions 61 and 66 
individually and simultaneously using the Change-IT Multiple Muta-
tion Site Directed Mutagenesis Kit (USB). All primer sequences used 
are described in Supplemental Table S1.
293FT cells were transfected with the lentiviral vector DNA, 
pCMV ∆8.2, and pLPVSVG plasmids using Lipofectamine 2000 (all 
from Life Technologies), and virus was collected 36 h posttransfec-
tion. This virus was then used to transduce desired cells for 24 h in 
presence of 7 μg/ml Polybrene (Sigma-Aldrich, St. Louis, MO). Cells 
were cultured normally for 5 d, after which they were selected using 
2 μg/ml puromycin (Sigma-Aldrich). Resistant colonies were picked 
after 4 d and expanded. siTRAF2 (Sigma-Aldrich) was used at a final 
50 nM concentration.
HA-tag immunoprecipitation and mass spectrophotometry
HA-tagged WT-CD30vOE and mutant T61_A CD30vOE cells, along 
with untagged-EGFP–expressing cells, were quickly washed with 
cold PBS+ (Life Technologies) twice, and 200 μl of 1× Cell Lysis 
Buffer (Cell Signaling Technology) containing 1 mM phenylmethyl-
sulfonyl fluoride (Sigma-Aldrich) and 1× phosphatase and protease 
inhibitors (F. Hoffmann-La Roche AG, Basel, Switzerland) were 
added per well of a six-well plate to at least four wells. Two duplicate 
wells were used for RNA and protein collection. The plate was incu-
bated on ice for 5 min, cells were scraped, and the resulting lysate 
was passed through a 30-gauge syringe multiple times and centri-
fuged at 14,000 × g for 15 min twice at 4ºC, and the supernatant 
was collected. A 100-μl amount was used for Western blot analysis, 
and 600 μl was used for immunoprecipitation using the Pierce HA 
Tag IP/Co-IP Kit (Thermo Fisher Scientific, Waltham, MA), following 
the manufacturer’s instructions. A 30-μl amount of eluate pooled 
was immediately neutralized with 1.5 μl of 1 M Tris, pH 9.5, and 
mass-spectrophotometric analysis was subsequently carried out.
Sample processing for tandem mass spectrometry
A 20-μl amount of the affinity eluate was reduced by the addition of 
NH4HCO3 (Sigma-Aldrich) to 50 mM SDS (Bio-Rad) to 2% and di-
thiothreitol (GE Healthcare, Little Chalfont, UK) to 20 mM. Samples 
were incubated for 16 h at 4°C, followed by 2 h at 22°C. The re-
duced proteins were then alkylated by the addition of iodoacet-
amide (GE Healthcare) to 50 mM and incubated at 22°C in the dark 
for 2 h. Protein was precipitated by acid precipitation (2-D Clean-up 
Kit; GE Healthcare) with an overnight final wash step to ensure the 
removal of all acid. Precipitated proteins were resuspended in 30 μl 
of 10% acetonitrile (J.T. Baker, Center Valley, PA) and 40 mM 
NH4HCO3 and digested with 0.5 μg of modified sequencing-grade 
trypsin and bovine pancreas (Roche) for 2 h at 37°C, followed by the 
addition of a further 0.5 μg of trypsin and incubation for 6 h at 37°C. 
The digest liquor was removed in vacuo and the residue reconsti-
tuted in 30 μl of 1% formic acid and 2% acetonitrile.
Tandem mass spectrometry. Acidified digests were analyzed by 
nano–high-performance liquid chromatography–tandem mass 
spectrometry using a Prominence nano HPLC system (Shiumadsu, 
Kyoto, Japan) interfaced with an Orbitrap Elite hybrid mass 
spectrometer (Thermo Fischer Scientific, Bremen, Germany). Digests 
were loaded onto a Reprosil aq C18 3-μm, 120-A, 300-μm trap (SGE 
pn-2222066) at 30 μl/min in 2% acetonitrile (ACN) and 0.1% (vol/vol) 
aqueous formic acid for 3.5 min at 50°C, then switched in-line with 
an analytical column (15 cm × 75 μm fused silica, self-packed) 
Reprosil aq C18 2.4-um (pn-r124.aq batch-9756, Dr. Maisch GmbH, 
Ammerbuch-Entringen, Germany) using a flow rate of 0.3 μl/min 
using small molecules that target T61 in CD30, and as a corollary 
may provide novel therapeutic modalities for HL and ALCL.
MATERIALS AND METHODS
Cell culture
HES2, HES3, and HES4 cells were grown feeder-free in either KOSR 
(Life Technologies, Carlsbad, CA) or NutriStem (Stemgent, Cam-
bridge, MA) with an additional 50 ng/ml basic fibroblast growth fac-
tor (b-FGF). Of note, ascorbate present in these media induces en-
dogenous CD30FL and CD30v expression, as previously reported 
by our lab. We showed that ascorbic acid is the sole component in 
KOSR medium that induces CD30 expression (Chung et al., 2010a,b; 
Thakar and Wolvetang, 2014). Matrigel (Life Technologies) was di-
luted in ice-cold KO-DMEM/F12 at 0.0347 mg/cm2 to coat tissue 
culture vessels before feeder-free culture. HES2 and HES4 hESCs 
that stably overexpress CD30v (CD30vOE) were cultured alongside 
and compared with control HES2 and HES4 hESCs that do not ex-
press any endogenous CD30v and CD30FL (CD30−). These CD30− 
and CD30vOE hESCs were generated in the E.J.W.’s lab and grown 
feeder-free in mouse embryonic fibroblast (MEF)–conditioned KOSR 
minus ascorbate (Life Technologies) with 100 ng/ml b-FGF to ensure 
the absence of endogenous CD30FL and CD30V expression. For 
preparation of MEF conditioned medium (CM), irradiated (30-Gy γ-
irradiation) MEF cells were seeded at 6 × 104 cells/cm2 in MEF me-
dium. After at least 4 h, the medium was replaced with either KOSR 
or KOSR minus ascorbate (0.3 ml/cm2) supplemented with 4 ng/ml 
b-FGF. CM was collected daily for 7–10 d, filtered through a 0.22-
μm filter, and supplemented with an additional 100 ng/ml b-FGF.
Cell cycle analysis
Cells were grown under pluripotency conditions as described earlier 
until they reached ∼60% confluence, and medium was changed on 
cells 8 h before commencement of assay to ensure minimal external 
factors affecting cell cycle. BD Cycletest Plus DNA Reagent Kit (BD 
Biosciences, San Jose, CA) was used as per manufacturer’s instruc-
tions to assess cell cycle. Analysis of the percentage of cells under 
each cell cycle phase was carried out using FCS4 Express software. 
Phospho-Histone H3 (Ser-10; 1:50; Cell Signaling Technology, 
Boston, MA) expression was measured using flow cytometry to de-
termine the percentage of cells undergoing mitosis. Cell counts 
were also performed for assessing proliferation. Equal numbers of 
cells were seeded into each of the six wells of a 24-well plate per 
condition (WT, T61A, and OE V/C). Each subsequent day, cells were 
dissociated from one well in each condition using TrypleE (Life Tech-
nologies) and counted subsequently using TC10 Automated Cell 
Counter (Bio-Rad Laboratories, Hercules, CA) as per manufacturer’s 
instructions.
Plasmids and generation of mutant and WT cells
We cloned the WT-CD30vOE (Wild-Type CD30-Variant Over-
Expression) cDNA sequence into pENTR 5′-TOPO TA vector using a 
pENTR 5′-TOPO TA cloning kit (Life Technologies). We then gener-
ated specific mutations (putative SUMOylation and USP7-binding 
sites) and deletions (putative SH2- and FHA-binding sites) using the 
Change-IT Multiple Mutation Site Directed Mutagenesis Kit (USB, 
Cleveland, OH). To facilitate generation of WT and mutant CD30v 
mammalian expression constructs, AGE1 (5′) and SAL1 (3′) restric-
tion sites were added to the Addgene plasmid 12252: pRRLSIN.
cPPT.PGK-GFP.WPRE (Didier Trono, Head of Laboratory of Virology 
and Genetics, EPFL School of Life Sciences).
We next generated N-terminally HA-tagged WT and mutant 
CD30vOE (T61_A, T66_A, and T61_66A) mammalian-expression 
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tions (Thermo Fisher Scientific) on either Typhoon (GE Healthcare) 
or V3-Western Workflow (Bio-Rad) for a densitometric representa-
tion. The images were respectively analyzed using either One-Rad 
(Bio-Rad) or Image Lab (Bio-Rad) software. All antibodies with work-
ing dilutions are described in Supplemental Table S2. Cytoplasmic 
and nuclear fractionation of cell lysates was carried out using NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher 
Scientific) according to the manufacturer’s instructions.
Immunofluorescence assays
Cells were washed three times with PBS, fixed with 3% paraformal-
dehyde, permeabilized with chilled 100% methanol at −20ºC for 
10 min, blocked in blocking buffer (5% BSA, 5% goat serum, 0.2% 
sodium azide, 0.3% Triton X-100 in PBS) for 1 h at room tempera-
ture, and incubated with desired primary antibodies overnight at 
4ºC. Next cells were washed three times with PBS and incubated for 
2 h at room temperature in the dark with species- and isotype-
matched Alexa Fluor–conjugated secondary antibodies (1:1000; 
Life Technologies), washed as before, mounted with ProLong Gold 
antifade reagent with 4′,6-diamidino-2-phenylindole (DAPI; Life 
Technologies), coverslipped, and sealed using nail polish. The cells 
were cured for 24 h at room temperature and then examined for 
staining using either using a QImaging-Retiga-EXi Fast 1394 fluo-
rescence microscope or Carl Zeiss LSM 710 for confocal microscopy 
at room temperature. Images were acquired with equal exposure 
and gain settings and were equally adjusted for brightness or con-
trast postacquisition. Secondary antibody–only treated cells were 
used as negative control. All antibodies with working dilutions are 
described in Supplemental Table S2.
H2O2 sensitivity assays
Cells were grown under pluripotency conditions as described ear-
lier until they reached ∼70% confluence in a six-well plate (for cell 
cycle and PI-based survival assays) or eight-well chamber slide (for 
immunofluorescence assay), and medium was changed 8 h before 
commencement of the assay. Cells were then subjected to 200 μM 
H2O2 for 3 h for immunofluorescence assay to detect active CAS-
PASE-3 expression. Cells were also subjected to 100 μM H2O2 for 
24 h to assess cell death via PI-based fluorescence assay and cell 
cycle. After H2O2 treatment, medium was pooled, and then the re-
maining cells were washed in PBS and dissociated and added to the 
pooled medium, spun, and resuspended in PBS. Half of the cells 
were subsequently stained with PI to measure cell death, and the 
other half was used to assess cell cycle using BD Cycletest Plus DNA 
Reagent Kit (BD Biosciences) as per manufacturer’s instructions. All 
antibodies with working dilutions are described in Supplemental 
Table S2.
Luciferase assays
HES3 cells were cultured in a 96-well plate and transfected with a 
mixture of 33 ng of β-galactosidase and either 33 ng of NFκB-
luciferase or 33 ng of AP1-luciferase expression plasmids with 
0.15 μl of Fugene-6 (Roche) to analyze NFκB or AP1 reporter activity 
48 h posttransfection. To that mix either 33 ng of CD30 plasmid 
(wild-type and various mutants) or 33 ng of siRNAs (TRAF2 or GFP) 
was added. These cells were next washed once with PBS and lysed 
with 150 μl of 1× Passive Lysis Buffer (Promega, Madison, WI). For 
luciferase assay, 50 μl of cell lysate was transferred to a white 96-well 
plate, and 100 μl of freshly dissolved luciferase assay buffer (E1501; 
Promega) was added per well and luminescence was read immedi-
ately on a SpectraMax M5 Microplate Reader (Molecular Devices, 
Sunnyvale, CA) to measure either NFκB or AP1 activity. For 
and 98% solvent A (0.1% [vol/vol] aqueous formic acid), 2% solvent 
B (80% [vol/vol] ACN, 0.1% [vol/vol] aqueous formic acid). Peptides 
were separated at 50°C using a sequence of linear gradients: to 
15% B over 5 min; to 47% B over 90 min; to 95% B over 10 min; and 
then holding the column at 95% B for 5 min. Eluate from the 
analytical column was introduced into the Orbitrap Elite throughout 
the entire run via a Nanospray Flex Ion Source (Thermo Fisher 
Scientific) and a 10-μm-inner-diameter uncoated silica emitter (New 
Objective, Woburn, MA). Typical spray voltage was 1.4 kV with no 
sheath, sweep, or auxiliary gases used. The heated capillary 
temperature was set to 285°C. The Orbitrap Elite was controlled 
using Xcalibur 2.2 software (Thermo Fisher Scientific) and operated 
in a data-dependent acquisition mode to automatically switch 
between Orbitrap-MS and ion trap-MS/MS. The survey full-scan 
mass spectra (from m/z 380 to 1700) were acquired in the Orbitrap 
with resolving power set to 240,000 (at 400 m/z) after accumulating 
ions to an automatic gain control (AGC) target value of 1.0 × 106 
charges in the LTQ. MS/MS spectra were concurrently acquired on 
the 15 most intense ions from the survey scan in the LTQ filled to an 
AGC target value of 3.0 × 104. Charge-state filtering, by which 
unassigned and charge state 1 precursor ions were not selected for 
fragmentation, and dynamic exclusion (repeat count 1, repeat 
duration 30 s, exclusion list size 500, exclusion duration 90 s) were 
used. Fragmentation conditions in the LTQ were 35% normalized 
collision energy; activation q of 0.25; 10-ms activation time; and 
minimum ion selection intensity, 5000 counts. Maximum ion injection 
times were 200 ms for survey full scans and 50 ms for MS/MS.
Data processing. Tandem mass spectra were processed using 
Proteome Discoverer (version 1.3; Thermo Fisher Scientific) and 
submitted to Mascot (version 2.2.06; Matrix Science, London, UK) 
with the following parameters specified: fixed modification, 
carbamido methyl-cysteine; variable modifications, deamidation 
(asparagine, glutamine) and oxidation (methionine); enzyme, 
trypsin; two missed cleavages; database, Uniprot human reference 
proteome (20120228) and bovine trypsin (65837 entries); MS 
tolerance, 10 ppm; MSMS tolerance, 0.8 Da.
Scaffold (version 3.6.4, Proteome Software, Portland, OR; Searle, 
2010) was used to validate Mascot protein identifications and com-
pare across samples. Scaffold probabilistically validates these pep-
tide identifications using PeptideProphet (Keller et al., 2002) and 
derives corresponding protein probabilities using ProteinProphet 
(Nesvizhskii et al., 2003). Two peptides per protein with ≥95% prob-
ability and an overall protein probability of ≥99% were required to 
assign a protein or protein group.
Western blot analysis
Cells were washed with phosphate-buffered saline (PBS) twice and 
subsequently lysed with 5× loading buffer (130 mM Tris, pH 6.8, 4% 
SDS, 0.02% bromophenol blue, 20% glycerol, 100 mM dithiothre-
itol) containing 10% PhosSTOP phosphatase inhibitor (Roche), 
homogenized with 30-guage syringe needles, heated at 80°C for 
10 min, and resolved using SDS–PAGE. The iBlot Dry Blotting 
System (Life Technologies) was used to transfer proteins onto a 
polyvinylidene fluoride membrane. Blots were blocked in blocking 
buffer (Tris-buffered saline, 0.01% Tween-20, 5% bovine serum albu-
min [BSA]) at room temperature for 2 h, probed with desired pri-
mary antibodies in blocking buffer at 4°C overnight with gentle agi-
tation, washed three times for 15 min each, probed with appropriate 
secondary antibodies in blocking buffer for 1 h at room tempera-
ture, washed as before, and detected using the Pierce ECL Western 
Blotting detection kit according to manufacturer’s recommenda-
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Statistical analysis
Data represent mean ± SD of the number (n) of independent ex-
periments unless indicated otherwise. Statistical significance was 
calculated by a two-way analysis of variance (ANOVA) with Bonfer-
roni posttests to compare replicate means between the indicated 
groups for all experiments, with the exception of phospho–Histone 
H3 quantification, for which one-way ANOVA with Dunnett post-
test was used.
β-galactosidase activity assessment (for normalization of well-to-well 
differences in transfection efficiency), 50 μl of cell lysate was trans-
ferred to a clear 96-well plate, and 100 μl of 1.5× β-galactosidase 
assay buffer was added per well. The plate was incubated at 37°C 
for 2 h and detected subsequently on SpectraMax M5 Microplate 
Reader. Each condition was performed in quintuplicate on each 
plate.
RNA isolation, cDNA synthesis, and quantitative PCR 
analysis
Total RNA was prepared using the RNA Purification kit (Macherey-
Nagel, Bethlehem, PA), and 1 μg of RNA was converted to cDNA in 
a 10-μl reaction mix with iScript cDNA synthesis kit (Bio-Rad), both 
according to manufacturer’s protocol. Quantitative PCRs used 
SsoFast EvaGreen Supermix (Bio-Rad) with cDNA template (from 
∼5 ng of RNA equivalent/reaction) according to manufacturer’s 
instructions using a C1000 Thermal Cycler (Bio-Rad). All primer 
sequences are listed in Supplemental Table S1. The expression 
value of each gene was normalized to a human β-actin control (Life 
Technologies). Relative gene expression was analyzed using soft-
ware C-1000 (Bio-Rad) and the ∆∆Ct method as described in Livak 
and Schmittgen (2001) and Briggs et al. (2012).
Flow cytometry analysis
Flow cytometry was performed on hESCs cultures in KOSR as previ-
ously described (Briggs et al., 2012), using appropriate primary an-
tibodies as described in Supplemental Table S2. Species- and iso-
type-matched Alexa Fluor–conjugated secondary antibodies 
(1:1000; Life Technologies) were used. Appropriate isotype control 
antibodies diluted at an identical final concentration as the primary 
antibodies were used as negative control for the experiments. 
Stained cells were analyzed by flow-cytometry using Accuri C6 FACS 
analyzer (BD Biosciences).
SUMOylation assay
SUMOylation assay was carried out using a SUMOlink in vitro 
SUMOylation assay kit (Active Motif, Carlsbad, CA). The assay was 
set up according to the manufacturer’s instructions. A 4.5-μg 
amount of CD30v protein was used for SDS–PAGE analysis, 
blocked, and subsequently stained with primary and secondary 
antibodies according to manufacturer’s instructions. Detection was 
carried out using Pierce ECL Western Blotting detection according 
to the manufacturer’s recommendation (Thermo Fisher Scientific) 
on a Typhoon Scanner (GE Healthcare).
Protein sequence and structure analysis
The sequence of CD30 was analyzed by Web-hosted bioinformat-
ics tools for similarities to other proteins: Blast (Altschul et al., 
1990); T-Coffee (Notredame et al., 2000); secondary structure pre-
diction (Jpred; Cuff and Barton, 2000); prediction of disordered 
regions (GeneSilico MetaDisorder; Kozlowski and Bujnicki, 2012); 
and fold recognition (I-Tasser; Roy et al., 2010). The structure pre-
diction method I-Tasser (Roy et al., 2010) predicts that CD30v 
could fold into a compact α/β domain, but the confidence of the 
prediction is very low. A homology model of TRAF2:CD30 frag-
ment was prepared using Modeller 9.9 (Eswar et al., 2008) based 
on the structures of TRAF3:CD40 fragment (Protein Data Bank 
[PDB] ID: 1FLL; Ni et al., 2000) and TRAF2:CD30 fragment (PDB 
ID: 1D01; Ye et al., 1999). For the preparation of the homology 
model, the sequences of CD30 and CD40 were aligned based on 
the structural superposition of TRAF2 and TRAF3 in the two 
structures.
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